top of page

Inflection Biosciences Announces Poster Presentation at the 2014 AACR Annual Meeting

Dublin, Ireland, March 24, 2014

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced a scheduled poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, in San Diego, California.

The poster presentation (Abstract #4524) entitled, “Combined inhibition of PIM and PI3 kinases shows an enhanced efficacy in a number of solid tumour cell lines” will be presented on Tuesday April 8, 2014 from 1:00 pm - 5:00 pm, Poster Session Experimental and Molecular Therapeutics 32, Hall A-E, Poster Section 30, Board number 10.

The abstract for the presentation made at the AACR Annual Meeting 2014 will be available at

About PIM/PI3 kinase inhibitors The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.

About Inflection Biosciences Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a pan-PIM kinase inhibitor program and a unique, dual acting pan-PIM/PI3 kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at

bottom of page